Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism

BACKGROUND Oxaliplatin (Oxa) is the first-line chemotherapy drug for colorectal cancer (CRC), and Oxa resistance is crucial for treatment failure. Prostaglandin F2α synthase (PGF2α) (PGFS), an enzyme that catalyzes the production of PGF2α, is involved in the proliferation and growth of a variety of tumors. However, the role of PGFS in Oxa resistance in CRC remains unclear. AIM To explore the role and related mechanisms of PGFS in mediating Oxa resistance in CRC. METHODS The PGFS expression level was examined in 37 pairs of CRC tissues and paracancerous tissues at both the mRNA and protein levels. Overexpression or knockdown of PGFS was performed in CRC cell lines with acquired Oxa resistance (HCT116-OxR and HCT8-OxR) and their parental cell lines (HCT116 and HCT8) to assess its influence on cell proliferation, chemoresistance, apoptosis, and DNA damage. For determination of the underlying mechanisms, CRC cells were examined for platinum-DNA adducts and reactive oxygen species (ROS) levels in the presence of a PGFS inhibitor or its products. RESULTS Both the protein and mRNA levels of PGFS were increased in the 37 examined CRC tissues compared to the adjacent normal tissues. Oxa induced PGFS expression in the parental HCT116 and HCT8 cells in a dose-dependent manner. Furthermore, overexpression of PGFS in parental CRC cells significantly attenuated Oxa-induced proliferative suppression, apoptosis, and DNA damage. In contrast, knockdown of PGFS in Oxa-resistant HCT116 and HCT8 cells (HCT116-OxR and HCT8-OxR) accentuated the effect of Oxa treatment in vitro and in vivo. The addition of the PGFS inhibitor indomethacin enhanced the cytotoxicity caused by Oxa. Treatment with the PGFS-catalyzed product PGF2α reversed the effect of PGFS knockdown on Oxa sensitivity. Interestingly, PGFS inhibited the formation of platinum-DNA adducts in a PGF2α-independent manner. PGF2α exerts its protective effect against DNA damage by reducing ROS levels. CONCLUSION PGFS promotes resistance to Oxa in CRC via both PGF2α-dependent and PGF2α-independent mechanisms.

[1]  F. He,et al.  CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response , 2021, Nucleic Acids Res..

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Y. Ruan,et al.  HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin , 2021, Drug development research.

[4]  J. Meyerhardt,et al.  NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Weiyi Qiu,et al.  PRSS contributes to cetuximab resistance in colorectal cancer , 2020, Science Advances.

[6]  N. Wolmark,et al.  Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Jeyasekharan,et al.  ROS and the DNA damage response in cancer , 2018, Redox biology.

[8]  L. Wyrwicz,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  W. Kuo,et al.  Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis , 2018, Journal of cellular physiology.

[10]  Yan Shen,et al.  Decreased Prostaglandin D2 Levels in Major Depressive Disorder Are Associated with Depression-Like Behaviors , 2017, The international journal of neuropsychopharmacology.

[11]  J. Taïeb,et al.  Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. , 2016, Journal of the National Cancer Institute.

[12]  Vida Kocbek,et al.  Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2α biosynthesis and action in ovarian endometriosis tissue and in model cell lines. , 2015, Chemico-biological interactions.

[13]  W. Nau,et al.  Cucurbiturils: from synthesis to high-affinity binding and catalysis. , 2015, Chemical Society reviews.

[14]  Y. Liu,et al.  AKR1C3 Overexpression Mediates Methotrexate Resistance in Choriocarcinoma Cells , 2014, International journal of medical sciences.

[15]  Chiaki Nakarai,et al.  Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer , 2014, Clinical and Experimental Medicine.

[16]  S. Fox,et al.  RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas , 2014, British Journal of Cancer.

[17]  O. El-Kabbani,et al.  Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. , 2013, Chemico-biological interactions.

[18]  L. Marnett,et al.  Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer , 2013, Journal of medicinal chemistry.

[19]  B. Friguet,et al.  Protein Oxidative Damage at the Crossroads of Cellular Senescence, Aging, and Age-Related Diseases , 2012, Oxidative medicine and cellular longevity.

[20]  D. MacLean,et al.  Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization , 2012, BMC Cancer.

[21]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[22]  Kikuko Watanabe.  Recent reports about enzymes related to the synthesis of prostaglandin (PG) F(2) (PGF(2α) and 9α, 11β-PGF(2)). , 2011, Journal of biochemistry.

[23]  Wei Zhou,et al.  LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. , 2011, World journal of gastroenterology.

[24]  Qing Yang,et al.  AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells , 2008, Molecular and Cellular Endocrinology.

[25]  D. Nie,et al.  Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.

[26]  A. C. Williams,et al.  Prostaglandin F2α stimulates motility and invasion in colorectal tumor cells , 2007 .

[27]  Kuang-Tai Kuo,et al.  Reversal of inflammation‐associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin , 2007, International journal of cancer.

[28]  V. Gandin,et al.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.

[29]  B. Stordal,et al.  Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells , 2006, Cancer Chemotherapy and Pharmacology.

[30]  J. Pitha,et al.  Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. , 2006, Endocrine-related cancer.

[31]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[32]  C. Tournigand,et al.  The evolving role of oxaliplatin in the management of colorectal cancer , 2003, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[33]  N. Sugino,et al.  Reactive oxygen species stimulate prostaglandin F2α production in human endometrial stromal cells in vitro , 2001 .

[34]  M. Nishizawa,et al.  cDNA cloning, expression and characterization of human prostaglandin F synthase 1 , 1999 .

[35]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.